# Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

> **NCT07270835** · PHASE4 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 40 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis
- B Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT07270835
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270835, "Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07270835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*